Endocrine Abstracts

Background: Adrenal incidentalomas (AI) represent incidentaly discovered adrenal mases, without simptoms or signs suggestive of adrenal pathology, at the time of visualization. It is well-known that overt or subclinical hypercorticism, as well as metabolic syndrome (MetS) harbour increased CV risk.There is still persisting debate on eventual cause-effect relationship of AI with metabolic syndrome MetS or probability of simply more frequent occurance of AI among these patients....

Cushing’s syndrome is a condition characterized by hypercortisolism (endogenous and exogenous) regardless of its etiology. Hypercortisolism caused by an adrenocorticotropin secreting pituitary adenoma is defined as Cushing’s disease. These tumors represent 10-12% of all pituitary adenomas. ACTH-secreting macroadenomas occur in only 4-23% of all patients with Cushing’s disease. We present the case of 56-year-old female patient with hypercortisolism and stigmata o...

Introduction: There is evidence that chronic mild hyponatremia (serum (Na+) 130–135 mmol/l) may have clinical consequences, such as fracture occurrence and neurological symptoms including unsteadiness, falls and attention deficits. These have been traditionally associated to water movement into nervous cells, as a result of the hypotonic state. The aim of the present study was to determine whether low extracellular sodium directly exerts negative effects on human neuronal...

Background: Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder characterized by impaired cortisol secretion and androgen excess. The mainstay of CAH treatment is glucocorticoid (GC) replacement, necessary to avoid adrenal crisis and manage androgen excess. The delicate balance between GC under/overtreatment is crucial to prevent metabolic and cardiovascular complications. Dual-release hydrocortisone (Plenadren®) is once-daily modified-release formulat...

Cushing’s syndrome (CS) is a severe disease associated with elevated morbidity and mortality rates, up to four times higher than those of general population. Whether the positive effects of cortisol-lowering medications is widely documented in overt CS cases, its impact on mild or subclinical CS remains unclear since limited clinical investigations have been performed in patients with subclinical hypercortisolism. In this study, we retrospectively analysed clinical data f...

Background: Significant treatment-related burdens accompany standard-of-care (SoC) therapies for acromegaly, which typically require healthcare-provider administration. CAM2029 is a novel, subcutaneous octreotide depot conveniently self-administered monthly by pre-filled syringe/injection pen. In a 24-week Phase 3 trial of CAM2029 in patients with acromegaly (ACROINNOVA 1, NCT04076462), insulin-like growth factor 1 (IGF-1) response was 72.2% in patients receiving CAM2029 vs 37...

Introduction: Liver Steatosis (LS) can be one of the metabolic complications of Cushing Syndrome (CS). The data on the impact of cortisol on liver function are very limited, according to one study the prevalence of LS in CS is 20%. However, the frequency seems to be much higher. Hepatic Steatosis Index (HSI) predicts LS based on ALT, AST, BMI, sex and co-existence of diabetes mellitus/impaired glucose intolerance. It can identify candidates for further liver examinations.<...

Cushing Syndrome (CS) is associated with a 18-fold higher risk of venous thromboembolism (VTE) when compared to the general population with the similar demographic characteristics. Despite numerous studies on hypercoagulability in CS, the unequivocal recommendations regarding timing and dosing of thromboprophylaxis in hypercortisolism are still lacking. We present a case series of patients with CS and VTE, hospitalized in the Endocrinology Department of University Hospital in ...

Introduction: Liver Steatosis(LS) can be one of the metabolic complications of Cushing Syndrome(CS). The data on the impact of cortisol on liver function are very limited, and there is only one study reporting a prevalence of LS of roughly 20%. Hepatic Steatosis Index (HSI) predicts LS based on ALT, AST, BMI, sex and co-existence of diabetes mellitus/impaired glucose intolerance.Objectives: To evaluate the prevalence of LS in patients with CS at the time...

Pasireotide is a a synthetic polypeptide second-generation somatostatin analogue that can be used in the treatment of GH- and ACTH- secreting pituitary neuroendocrine tumors (PitNETs), however, there are single reports of pasireotide treatment in other subtype of PitNETs. We present a case series of aggressive, giant PitNETs treated with pasireotide alone or as multimodal therapy.Case 1: A 33-year-old male reported to the Clinic due to severe headaches a...